Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Rectal Neoplasms 3Esophageal Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Solid Tumors Harboring NTRK Fusion 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Papillomavirus Infections 1Ovarian Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

Vincristine 3Radiotherapy 3Radiation 3Dactinomycin 3Cyclophosphamide 3Vinorelbine 2Magnetic Resonance Spectroscopy 2Biopsy 2temsirolimus 1ganitumab 1efineptakin alfa 1dinutuximab 1X-Rays 1Specimen Handling 1Sirolimus 1Receptor Protein-Tyrosine Kinases 1Phantoms, Imaging 1Irinotecan 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma, Embryonal × Receptor Protein-Tyrosine Kinases × Clear all
NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
14 enrolled 17 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡